Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 18, 2015, Pages 5797-5802

  Ebert, Gregor ^a,b   Preston, Simon ^a,b   Allison, Cody ^a,b   Cooney, James ^a   Toe, Jesse G ^a,b   Stutz, Michael D ^a,b   Ojaimi, Samar ^a,b   Scott, Hamish W ^a   Baschuk, Nikola ^c   Nachbur, Ueli ^a,b   Torresi, Joseph ^b   Chin, Ruth ^b   Colledge, Danielle ^d   Li, Xin ^d   Warner, Nadia ^d   Revill, Peter ^d   Bowden, Scott ^d   Silke, John ^a,b   Begley, C Glenn ^e   Pellegrini, Marc ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^e TetraLogic Pharmaceuticals   (United States)

Author keywords

Cellular inhibitor of apoptosis proteins; cIAP1; cIAP2; Hepatitis B virus; TNF

Indexed keywords

HOST FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR; BIRC2 PROTEIN, MOUSE; BIRC3 PROTEIN, MOUSE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HOST CELL; IMMUNOCOMPETENT CELL; INFECTION CONTROL; LIVER CELL; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; GENOTYPE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LIVER TUMOR; METABOLISM; PHENOTYPE; VIROLOGY;

ANIMALIA; HEPATITIS B VIRUS; MUS;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CYTOKINES; DISEASE MODELS, ANIMAL; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 84928920391     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502390112     Document Type: Article

References (34)

1. WHO (2009) Hepatitis B vaccines. Wkly Epidemiol Rec 84(40):405-419.
2. Lozano R, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095-2128.
3. Ganem D, Prince AM (2004) Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350(11):1118-1129.
4. Shale MJ, et al. (2010) Review article: Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 31(1):20-34.
5. Vassilopoulos D, Calabrese LH (2007) Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 19(6):619-625.
6. Huang LR, Wu HL, Chen PJ, Chen DS (2006) An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 103(47):17862-17867.
7. Yang PL, et al. (2010) Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 107(2):798-802.
8. Tzeng HT, et al. (2014) Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS ONE 9(7):e103008.
9. Guidotti LG, et al. (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4(1):25-36.
10. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV (1997) Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 158(12):5692-5697.
11. Thimme R, et al. (2003) CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77(1):68-76.
12. Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76(1):34-40.
13. Sheehan KC, et al. (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/ beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26(11):804-819.
14. Teijaro JR, et al. (2013) Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340(6129):207-211.
15. Wilson EB, et al. (2013) Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340(6129):202-207.
16. Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101(17):6669-6674.
17. Lütgehetmann M, et al. (2011) Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 140(7):2074-2083.
18. Lang KS, et al. (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11(2):138-145.
19. Marinos G, et al. (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108(5):1453-1463.
20. Silke J (2011) The regulation of TNF signalling: What a tangled web we weave. Curr Opin Immunol 23(5):620-626.
21. Bertrand MJ, et al. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30(6):689-700.
22. Feltham R, et al. (2010) Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem 285(23):17525-17536.
23. Mahoney DJ, et al. (2008) Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(33):11778-11783.
24. Varfolomeev E, et al. (2008) c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 283(36):24295-24299.
25. Vince JE, et al. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682-693.
26. Benetatos CA, et al. (2014) Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 13(4):867-879.
27. Pérarnau B, et al. (1999) Single H2Kb, H2Db and double H2KbDb knockout mice: Peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol 29(4):1243-1252.
28. Kägi D, et al. (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369(6475):31-37.
29. Dalton DK, et al. (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259(5102):1739-1742.
30. Malissen M, et al. (1995) Altered T cell development in mice with a targeted mutation of the CD3-ε gene. EMBO J 14(19):4641-4653.
31. Spanopoulou E, et al. (1994) Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. Genes Dev 8(9):1030-1042.
32. Schile AJ, García-Fernández M, Steller H (2008) Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev 22(16):2256-2266.
33. Gardam S, et al. (2011) Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 117(15):4041-4051.
34. Postic C, et al. (1999) Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274(1):305-315.